- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 02.04. | Dividendenbekanntmachungen (02.04.2026) | 18.895 | wallstreetONLINE (Dividenden) | Unternehmen ISIN-Code Dividende (Währung) Dividende (EUR) ABM INDUSTRIES INC US0009571003 0,29 USD 0,2501 EUR AKTIA BANK PLC FI4000058870 - 0,8 EUR ALICO INC US0162301040 0,05 USD 0,0431... ► Artikel lesen | |
| 18.03. | XOMA Corp - 8.375% DP PFD B declares $0.5234 dividend | 1 | Seeking Alpha | ||
| 18.03. | XOMA Preferred Shares Series A declares $0.5391 dividend | 5 | Seeking Alpha | ||
| 18.03. | XOMA Royalty Corporation: XOMA Royalty Declares Quarterly Preferred Stock Dividends | 3 | GlobeNewswire (USA) | ||
| 18.03. | XOMA Royalty Corp - S-8, Securities to be offered to employees in employee benefit plans | 1 | SEC Filings | ||
| XOMA CORPORATION PREF Aktie jetzt für 0€ handeln | |||||
| 18.03. | XOMA Royalty Corp - 10-K, Annual Report | 1 | SEC Filings | ||
| 18.03. | XOMA Q1 2026 slides: royalty receipts surge 68%, portfolio tops 120 assets | 2 | Investing.com | ||
| 18.03. | XOMA-Aktie legt um 7 % zu: Starke Lizenzeinnahmen treiben Gewinn und Umsatz über Erwartungen | 1 | Investing.com Deutsch | ||
| 18.03. | XOMA Royalty Corp - 8-K, Current Report | - | SEC Filings | ||
| 18.03. | XOMA GAAP EPS of $0.26 beats by $0.39, revenue of $13.76M beats by $2.71M | 7 | Seeking Alpha | ||
| 18.03. | XOMA Royalty Corporation: XOMA Royalty Reports 2025 Financial Results and Highlights Recent Business Achievements | 646 | GlobeNewswire (Europe) | Portfolio receipts: • Achieved over $50 million of cash receipts, including $33.6 million in royalties and $16.9 million milestones, in full year 2025 • Total receipts increased 9% with royalties... ► Artikel lesen | |
| 17.03. | XOMA FY Earnings Preview | 1 | Seeking Alpha | ||
| 12.03. | XOMA Royalty Corporation: XOMA Royalty to Report Fourth Quarter and Full Year 2025 Financial Results on March 18, 2026 | 5 | GlobeNewswire (USA) | ||
| 02.03. | XOMA Royalty Corp - 8-K, Current Report | - | SEC Filings | ||
| 24.02. | Leerink raises Xoma stock price target on royalty outlook | 8 | Investing.com | ||
| 12.02. | Xoma stock rating reinstated as Hold by TD Cowen after Generation Bio acquisition | 5 | Investing.com | ||
| 09.02. | XOMA Royalty schließt Übernahme von Generation Bio ab; GBIO-Aktie wird von der NASDAQ delistet | 3 | Investing.com Deutsch | ||
| 09.02. | XOMA Royalty Corp - 8-K, Current Report | 2 | SEC Filings | ||
| 09.02. | XOMA Royalty Corporation: XOMA Royalty Announces Closing of Tender Offer and Completed Acquisition of Generation Bio, Inc. | 496 | GlobeNewswire (Europe) | EMERYVILLE, Calif., Feb. 09, 2026 (GLOBE NEWSWIRE) -- XOMA Royalty Corporation (NASDAQ: XOMA) ("XOMA Royalty" or the "Company"), a biotechnology royalty aggregator playing a distinctive role in helping... ► Artikel lesen | |
| 12.01. | XOMA Royalty announces CFO transition | 11 | Seeking Alpha |
1 2 3 4 Weiter >>
79 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| ARCELLX | 115,03 | -0,01 % | Arcellx, Inc. - 10-K/A, Annual Report | ||
| SUMMIT THERAPEUTICS | 22,080 | -0,81 % | Stifel reiterates Summit Therapeutics stock rating on trial data | ||
| QIAGEN | 32,580 | +0,12 % | Aktien New York Ausblick: Moderate Gewinne - Lage in Nahost sorgt für Vorsicht | NEW YORK (dpa-AFX) - Am US-Aktienmarkt werden am Dienstag zum Handelsstart moderate Gewinne erwartet. Angesichts der unsicheren Lage in Nahost dominiert - wie bereits zum Wochenstart - die Vorsicht.... ► Artikel lesen | |
| ERASCA | 21,490 | -4,40 % | Erasca, Inc. - 8-K, Current Report | ||
| ADMA BIOLOGICS | 11,260 | +1,67 % | ADMA vs Takeda: Which Plasma Therapy Stock Is the Better Buy Today? | ||
| BEAM THERAPEUTICS | 27,105 | -10,13 % | Beam Therapeutics Announces Compelling Updated Clinical Data from the Ongoing Phase 1/2 Trial of BEAM-302 in Alpha-1 Antitrypsin Deficiency (AATD) to Support Advancement to Pivotal Development | Treatment with 60 mg of BEAM-302 Led to Mean Steady-state Total AAT Level of 16.1 µM and All Patients Consistently and Durably Above the 11 µM Protective AAT Threshold with up to 12 Months of Follow-up... ► Artikel lesen | |
| RELAY THERAPEUTICS | 15,130 | +0,33 % | Relay Therapeutics, Inc.: Relay Therapeutics Announces Data from Zovegalisib + Fulvestrant at the Phase 3 Dose of 400mg BID Fed at ESMO Targeted Anticancer Therapies Congress 2026 | 400mg BID fed is the dose used in the ongoing Phase 3 ReDiscover-2 trial, which initiated mid-2025 11.1-month median PFS in heavily pre-treated patients with PI3Ka-mutated, HR+/HER2- metastatic breast... ► Artikel lesen | |
| TANGO THERAPEUTICS | 25,760 | -0,43 % | Stifel reiterates Tango Therapeutics stock rating on combo potential | ||
| ENVERIC BIOSCIENCES | 5,020 | +24,57 % | What's Going On With Enveric Biosciences Stock On Friday? | ||
| EVOTEC | 5,350 | -0,93 % | Evotec hebt ab: Kursziel übertroffen, Experten uneinig - Wie geht es jetzt weiter? | ||
| VERA THERAPEUTICS | 37,700 | -1,80 % | Vera Therapeutics Appoints Jane Wright-Mitchell as Chief Legal Officer | BRISBANE, Calif., March 25, 2026 (GLOBE NEWSWIRE) -- Vera Therapeutics, Inc. (Nasdaq: VERA), a biotechnology company focused on developing and commercializing transformative treatments for patients... ► Artikel lesen | |
| NUVALENT | 104,53 | -3,28 % | Nuvalent präsentiert AACR-Daten vor PDUFA-Entscheid im September | ||
| BIONTECH | 90,15 | +0,22 % | Durchbruch in der Psychotherapie: Emyria meldet 50% Remission - Ein neuer "BioNTech-Moment" für die Mental-Health-Branche? | ||
| FIRST TRACKS BIOTHERAPEUTICS | 18,160 | -4,47 % | AnaptysBio, Inc.: Anaptys Completes Separation of First Tracks Biotherapeutics and Now Exclusively Manages GSK and Vanda Financial Collaborations | Focused on protecting and returning value of Jemperli and imsidolimab royalties to shareholdersLaunches with virtual model, including limited FTEs and minimal operating expenses, and approximately... ► Artikel lesen | |
| MAPLIGHT THERAPEUTICS | 29,760 | +2,62 % | MapLight Therapeutics, Inc.: MapLight Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update | Phase 2 ZEPHYR trial of ML-007C-MA for schizophrenia expected to reach target enrollment (n=300) in April 2026, with topline results expected in the third quarter of 2026Phase 2 IRIS trial for ML-004... ► Artikel lesen |
XOMA CORPORATION PREF gehört der Branche Biotechnologie an. Mit einer aktuellen Kursveränderung von 0,000 (0,00 %) liegt der Kurs bei 20,800 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu XOMA CORPORATION PREF finden Sie auf Wallstreet Online.